Adjuvant Chemotherapy in Elderly Patients with Non-Small-Cell Lung Cancer

Cesare Gridelli, MD, Paolo Maione, MD, Daniela Comunale, MD, and Antonio Rossi, MD

Disclosures

Cancer Control. 2007;14(1):57-62. 

In This Article

Conclusions

Standard adjuvant treatment of NSCLC in elderly patients is a controversial topic because of the lack of specific prospective data. As occurred for large randomized trials of platin-based chemotherapy in advanced disease, retrospective subgroup analysis on elderly patients enrolled in the above-mentioned adjuvant trials performed in the young population will be presented in the near future. Although these analyses could suffer from selection bias, in the future they might be the unique source of scientific data on adjuvant chemotherapy for elderly patients with NSCLC. Although specifically designed prospective trials are needed to elucidate the role of this approach in the elderly, the potential low accrual rate on surgical adjuvant trials could be a limit. Possible future research directions in the adjuvant treatment of elderly patients with early-stage NSCLC include attenuated-dose platinbased chemotherapy, third-generation single-agent chemotherapy (vinorelbine, gemcitabine, taxanes), and targeted therapies with or without chemotherapy.

CME Information

The print version of this article was originally certified for CME credit. For accreditation details, contact the
publisher . H. Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, Tampa, FL 33612. Telephone: (813) 632-1349. Fax: (813) 903-4950. Email: ccjournal@moffitt.usf.edu .

Comments

3090D553-9492-4563-8681-AD288FA52ACE

processing....